Biomerieux SA Total Liabilities
Biomerieux SA total liabilities. Based on the latest financial reports, Biomerieux SA (BIM) has total liabilities worth €1.47 Billion EUR (≈ $1.72 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check how resilient are Biomerieux SA's assets to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Biomerieux SA (2005–2025)
Total liabilities of Biomerieux SA from 2005 to 2025. This chart illustrates how Biomerieux SA's total liabilities have evolved over time, based on quarterly financial data. Explore Biomerieux SA long-term investment allocation to see how much of total assets are deployed in long-term investments.
Biomerieux SA Competitors by Total Liabilities
The table below lists competitors of Biomerieux SA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
DISCOVERY LTD(UNSP.ADR)/3
F:D3H0
|
Germany | €288.99 Billion |
|
Orion Oyj B
HE:ORNBV
|
Finland | €726.20 Million |
|
Primerica Inc
NYSE:PRI
|
USA | $12.16 Billion |
|
UNICHARM CORP. SP.ADR 1
F:UN41
|
Germany | €331.92 Billion |
|
HudBay Minerals Inc
TO:HBM
|
Canada | CA$2.90 Billion |
|
Alpha Services and Holdings S.A.
AT:ALPHA
|
Greece | €64.85 Billion |
|
RHB Bank Bhd
KLSE:1066
|
Malaysia | RM323.91 Billion |
|
Quinenco
SN:QUINENCO
|
Chile | CL$52.97 Trillion |
Liability Composition Analysis (2005–2025)
This chart breaks down Biomerieux SA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is Biomerieux SA's balance sheet.
Liquidity & Leverage Metrics
Biomerieux SA Total Liabilities Ratios Explained
Biomerieux SA total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.39 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | 0.29 | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.36 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.26 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Biomerieux SA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Biomerieux SA (2005–2025)
The table below shows the annual total liabilities of Biomerieux SA from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €1.47 Billion ≈ $1.72 Billion |
-5.79% |
| 2024-12-31 | €1.56 Billion ≈ $1.82 Billion |
+3.45% |
| 2023-12-31 | €1.51 Billion ≈ $1.76 Billion |
-2.38% |
| 2022-12-31 | €1.54 Billion ≈ $1.80 Billion |
+7.10% |
| 2021-12-31 | €1.44 Billion ≈ $1.69 Billion |
-0.35% |
| 2020-12-31 | €1.45 Billion ≈ $1.69 Billion |
-5.29% |
| 2019-12-31 | €1.53 Billion ≈ $1.79 Billion |
+1.66% |
| 2018-12-31 | €1.50 Billion ≈ $1.76 Billion |
+19.88% |
| 2017-12-31 | €1.25 Billion ≈ $1.47 Billion |
-10.96% |
| 2016-12-31 | €1.41 Billion ≈ $1.65 Billion |
+10.74% |
| 2015-12-31 | €1.27 Billion ≈ $1.49 Billion |
+6.65% |
| 2014-12-31 | €1.19 Billion ≈ $1.39 Billion |
+28.25% |
| 2013-12-31 | €929.30 Million ≈ $1.09 Billion |
+46.81% |
| 2012-12-31 | €633.00 Million ≈ $740.04 Million |
-3.92% |
| 2011-12-31 | €658.80 Million ≈ $770.21 Million |
+39.40% |
| 2010-12-31 | €472.60 Million ≈ $552.52 Million |
+4.26% |
| 2009-12-31 | €453.30 Million ≈ $529.96 Million |
-9.48% |
| 2008-12-31 | €500.80 Million ≈ $585.49 Million |
+26.11% |
| 2007-12-31 | €397.10 Million ≈ $464.25 Million |
+3.93% |
| 2006-12-31 | €382.10 Million ≈ $446.72 Million |
-6.26% |
| 2005-12-31 | €407.60 Million ≈ $476.53 Million |
-- |
About Biomerieux SA
bioMérieux S.A. develops, manufactures, and markets in vitro diagnostic solutions for infectious diseases in France, Europe, Africa, the Middle East, North and South America, the Asia Pacific, and internationally. It operates through Clinical Applications and Industrial Applications segments. The company offers CHROMID RANGE, a chromogen culture media; air, surface, and water monitoring systems; … Read more